Sam Backenroth

Aspargo Labs, Inc., is a pharmaceutical company led by an experienced team of drug developers focused on enhancing the delivery of the world’s most meaningful medications through highly absorbent liquid oral suspension sprays. The Company’s proprietary platform applies advanced pharmaceutical principles to accelerate the path to commercialization of products utilizing known active pharmaceutical ingredients. Aspargo’s oral suspension platform is custom designed to optimize each molecule’s unique properties to better align with patient needs, achieving rapid therapeutic exposure while offering key advantages including improved absorption, ease of administration, flexible dosing, and enhanced patient adherence. The Company is leveraging its integrated development platform across multiple therapeutic areas, beginning with a liquid oral sildenafil suspension spray currently marketed by Aspargo in multiple countries.

Immunewalk Therapeutics is a clinic stage biotechnology company developing therapeutics for immune and inflammatory diseases. The company’s lead program is an antibody targeting monocytes that blocks their ability to traverse into inflammatory tissue. Robust activity has been demonstrated in animal models and ex-Vivo patient samples of multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, MASH, and uveitis.

Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing scientific, clinical, regulatory, and commercial expertise, Eyexora advances a diversified pipeline of therapies and devices through focused subsidiaries, to reduce risk, improve efficiency, and scale impact. Founded by leaders with decades of ophthalmology experience and a track record of more than 30 successful company and product launches, Eyexora partners with clinician-scientists and research institutes worldwide to bring transformative eye care solutions to patients faster and smarter.

LS Associates' mission is to provide experienced, interim and fractional C-level leaders who can immediately partner with executive teams, board members, and investors to solve complex business problems and facilitate growth. Our seasoned, on-demand bench of over 150 executives have experience guiding private and public life science companies through every stage of growth or change management, from inception to maturity. We are executors who are confident in our ability to take calculated risks, adeptly steer businesses, and make decisions with unwavering certainty.

VBL Therapeutics is a late stage biotechnology company using the machinery of the body to precisely address disease progression. We have developed an arsenal of gene targeting and antibody platforms and created a pipeline of exquisite solutions for people with cancer and chronic inflammatory disease. Our lead program, VB-111, is currently enrolling a Phase 3 trial in ovarian cancer, with data anticipated in 2H22.

Orphion Therapeutics is a private gene therapy company focused on one time curative treatments for ultra-rare pediatric ocular diseases.

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs. Using PATrOL™ technology, NeuBase aims to first tackle rare, genetic diseases including Huntington's disease and Myotonic Dystrophy.